Letermovir Prophylaxis for High-Risk Allogenic Transplantation Recipients, Real- World Israeli Experience
Sigal Grisariu Greenzaid(Hadassah Medical Center), Batia Avni(Hadassah Medical Center), Polina Stepensky(Hebrew University of Jerusalem), Mona Kazuli(Hadassah Medical Center), Yael Bar‐On(Tel Aviv University), Ron Ram(Tel Aviv University), Odelia Amit(Tel Aviv University), Adir Shaulov(Hadassah Medical Center), Eran Zimran(Hebrew University of Jerusalem), Dana Yehudai‐Ofir(Rambam Health Care Campus), Liat Shargian(Tel Aviv University), Tsila Zuckerman(Johannes Gutenberg University Mainz), Moshe Yeshurun, Jacob Strahilevitz(Hebrew University of Jerusalem)
Cited by 0
Related Papers
Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase
|Nature Medicine|2005|1k
Plasmid-Mediated Quinolone Resistance: a Multifaceted Threat
|Clinical Microbiology Reviews|2009|930
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
|New England Journal of Medicine|2020|859
<i>qnr</i> Prevalence in Ceftazidime-Resistant <i>Enterobacteriaceae</i> Isolates from the United States
|Antimicrobial Agents and Chemotherapy|2006|576
Plasmid-Mediated Quinolone Resistance
|Microbiology Spectrum|2014|469